TCR2 Therapeutics Inc
F:2K7
Fundamental Analysis

Revenue & Expenses Breakdown
TCR2 Therapeutics Inc
Balance Sheet Decomposition
TCR2 Therapeutics Inc
Current Assets | 140.5m |
Cash & Short-Term Investments | 110.3m |
Other Current Assets | 30.2m |
Non-Current Assets | 11m |
PP&E | 9.2m |
Other Non-Current Assets | 1.9m |
Free Cash Flow Analysis
TCR2 Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
TCR2 Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-131.4m
USD
|
Operating Income
|
-131.4m
USD
|
Other Expenses
|
-31.7m
USD
|
Net Income
|
-163.1m
USD
|
2K7 Profitability Score
Profitability Due Diligence
TCR2 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
TCR2 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
2K7 Solvency Score
Solvency Due Diligence
TCR2 Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
TCR2 Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
2K7 Price Targets Summary
TCR2 Therapeutics Inc
Dividends
Current shareholder yield for 2K7 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?